Pamiparib
Pamiparib Uses, Dosage, Side Effects, Food Interaction and all others data.
Pamiparib is under investigation in clinical trial NCT03933761 (Pamiparib in Fusion Positive, Reversion Negative High Grade Serous Ovarian Cancer or Carcinosarcoma With BRCA1/2 Gene Mutations If Progression on Substrate Poly ADP Ribose Polymerase Inhibitbor (PARPI) or Chemotherapy).
| Trade Name | Pamiparib |
| Generic | Pamiparib |
| Pamiparib Other Names | Pamiparib |
| Type | |
| Formula | C16H15FN4O |
| Weight | Average: 298.321 Monoisotopic: 298.122989282 |
| Groups | Investigational |
| Therapeutic Class | |
| Manufacturer | |
| Available Country | |
| Last Updated: | September 19, 2023 at 7:00 am |
Innovators Monograph
You find simplified version here Pamiparib
